EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

New Horizons with Growth Differentiation Factor 15 in Oncology: From Cancer Cachexia and Tumour Immunity to Novel Therapeutic Strategies

Keiji Sugiyama iD, Naureen Starling iD, Ian Chau iD

Current Oncology · 2025

DOI: 10.3390/curroncol32110604 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, 2025. Verfasst von Keiji Sugiyama und 2 weiteren Autor:innen. Beteiligte Einrichtung: Gastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, London SW3 6JJ, UK. Hauptthemen laut MEDLINE: Growth Differentiation Factor 15, Cachexia, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Growth differentiation factor 15 (GDF-15) is a stress-induced cytokine produced by tumour cells and peripheral cells. It is implicated in the development of cancer cachexia, a debilitating condition for which no effective pharmacological therapy currently exists. GDF-15 regulates appetite and metabolic processes through complex neural and hormonal networks. Furthermore, it has been implicated in chemotherapy-induced nausea and vomiting, representing a potential therapeutic target. GDF-15 negatively affects tumour immunity, suggesting that anti-GDF-15 therapy could potentially enhance immune responses and help overcome resistance to immunotherapy. Recently, early clinical trials have reported preliminary results of GDF-15-targeted therapies in alleviating cancer cachexia and potentially enhancing the efficacy of immunotherapy. This review aims to provide an overview of the role of GDF-15 in cancer cachexia, including the underlying neural mechanisms and their involvement in tumour immunity. This review also summarises recent clinical trial findings and discusses future perspectives on GDF-15-targeted therapy in oncology, offering important insights for future research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Growth Differentiation Factor 15CachexiaNeoplasmsHumansImmunotherapy

Stichwörter der Autor:innen

autonomic nervous systemcancer cachexiagrowth differentiation factor 15immune checkpoint inhibitors

Substanzen

Growth Differentiation Factor 15GDF15 protein, human

Autor:innen und Institutionen

  • Gastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, London SW3 6JJ, UK.
  • Department of Medical Oncology, NHO Nagoya Medical Center, Nagoya 460-0001, Aichi, Japan.

ORCID-Profile: Keiji Sugiyama, Naureen Starling, Ian Chau

Zitieren

APA

Sugiyama, K., Starling, N., & Chau, I. (2025). New Horizons with Growth Differentiation Factor 15 in Oncology: From Cancer Cachexia and Tumour Immunity to Novel Therapeutic Strategies. Current Oncology. https://doi.org/10.3390/curroncol32110604

Vancouver

Sugiyama K, Starling N, Chau I. New Horizons with Growth Differentiation Factor 15 in Oncology: From Cancer Cachexia and Tumour Immunity to Novel Therapeutic Strategies. Current Oncology. 2025. doi:10.3390/curroncol32110604

BibTeX
@article{Sugiyama2025,
  author = {Sugiyama, Keiji and Starling, Naureen and Chau, Ian},
  title = {New Horizons with Growth Differentiation Factor 15 in Oncology: From Cancer Cachexia and Tumour Immunity to Novel Therapeutic Strategies},
  journal = {Current Oncology},
  year = {2025},
  doi = {10.3390/curroncol32110604}
}
Kostenlos starten →